| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Rift Valley Fever Virus DIVA vaccine
Record information and status
Record ID
Date of creation
2020-06-18 15:00 UTC (austein.mcloughlin@cbd.int)
Date of last update
2020-07-27 16:02 UTC (austein.mcloughlin@cbd.int)
Date of publication
2020-07-27 16:02 UTC (austein.mcloughlin@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Rift Valley Fever Virus DIVA vaccine
Transformation event
Dr. George Warimwe
Principal Scientist
International Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom
ChAdOx1-GnGc is a DIVA (differentiating infected from vaccinated animals) vaccine composed of a replication-deficient simian adenovirus vector expressing Rift valley fever phlebovirus envelope glycoproteins (amino-terminus and carboxy-terminus glycoproteins). Together, the glycoproteins form virus-like particles, which are expected to elicit a strong immune response to viral challenges in livestock, such as sheep, goats, cattle and dromedary camels. The disease is characterized by high rates of mortality in newborn animals and abortions in those that are pregnant. The modified adenovirus is not expected to replicate within the animal due to the deletion of gene E1, which is responsible for replication.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Chimpanzee adenovirus Y25 - ChAd Y25
Point of collection or acquisition of the recipient organism
ChAdOx1 (Chimpanzee Adenovirus Oxford 1) is a replication-deficient vaccine vector derived from Chimpanzee adenovirus Y25 and contains a deletion of the gene responsible for replication, E1.
Characteristics of the transformation process
Techniques used for the modification
  • Direct DNA transfer
Genetic elements construct
Major immediate early promoter containing intron A
0.00 Kb
Human tissue plasminogen activator leader sequence
0.00 Kb
Glycoprotein Gn
0.00 Kb
Glycoprotein Gc
0.00 Kb
Bovine growth hormone terminator
0.00 Kb
Further details
Notes regarding the genetic elements introduced or modified in this LMO
Gene expression
Transcription of the Rift valley fever phlebovirus glycoproteins Gn and Gc are under control of the Human cytomegalovirus major immediate-early promoter and the Bos taurus bovine growth hormone terminator. A human tissue plasminogen activator leader sequence is also included to enhance the expression of the glycoproteins.

- The Human cytomegalovirus immediate early promoter contains intron A, which enhances expression of the downstream elements by promoting strong transcription.
- The Human cytomegalovirus immediate early promoter contains the following portions: Regulatory sequence (437 bp); Enhancer (481 bp); Promoter (62 bp); Exon A (120 bp); and Intron A (824 bp) (total size 1924 bp).
- The Rift valley fever virus glycoproteins Gn and Gc were isolated from the M segment of the viral genome (base pairs: 411 to 3614)

Please note: Genetic element sizes have not been confirmed
LMO characteristics
Modified traits
Common use(s)
  • Vaccine

Records referencing this document (2)
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record